Compare ELMD & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | PROF |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.1M | 238.1M |
| IPO Year | 2010 | 2017 |
| Metric | ELMD | PROF |
|---|---|---|
| Price | $25.58 | $6.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $36.00 | $12.00 |
| AVG Volume (30 Days) | 25.2K | ★ 83.4K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.55 | 25.89 |
| EPS | 0.56 | ★ 1.41 |
| Revenue | ★ $54,716,000.00 | $16,098,000.00 |
| Revenue This Year | $15.59 | $92.40 |
| Revenue Next Year | $11.51 | $64.10 |
| P/E Ratio | $45.97 | ★ $4.83 |
| Revenue Growth | 13.83 | ★ 50.73 |
| 52 Week Low | $17.73 | $3.92 |
| 52 Week High | $30.73 | $8.95 |
| Indicator | ELMD | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 56.97 |
| Support Level | $23.29 | $5.75 |
| Resistance Level | $26.84 | $7.07 |
| Average True Range (ATR) | 0.77 | 0.40 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 41.40 | 74.07 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.